The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Issue 13 (8th June 2022)

• Record Type: Journal Article
• Authors: Stenzl, Arnulf; Szmulewitz, Russell Z.; Petrylak, Daniel; Holzbeierlein, Jeffrey; Villers, Arnauld; Azad, Arun; Alcaraz, Antonio; Alekseev, Boris; Iguchi, Taro; Shore, Neal D.; Gomez‐Veiga, Francisco; Ivanescu, Cristina; Rosbrook, Brad; Ramaswamy, Krishnan; Ganguli, Arijit; Haas, Gabriel P.; Armstrong, Andrew J.
• Is Part Of: Prostate. Volume 82:Issue 13(2022)
• Page Start: 1237
• Page End: 1247
• Publication Date: 2022-06-08
• Subjects: enzalutamide -- metastatic hormone‐sensitive -- prostate cancer; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.24396
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Background: Enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression‐free survival versus ADT alone in patients with metastatic hormone‐sensitive prostate cancer (mHSPC) in ARCHES (NCT02677896). While health‐related quality of life (HRQoL) was generally maintained in the intent‐to‐treat population, we further analyzed patient‐reported outcomes (PROs) in defined subgroups. Methods: ARCHES was a randomized, double‐blind, placebo‐controlled, phase 3 study. Patients with mHSPC received enzalutamide (160 mg/day) plus ADT ( n = 574) or placebo plus ADT ( n = 576). Questionnaires, including the Functional Assessment of Cancer Therapy−Prostate, Brief Pain Inventory−Short Form, and EuroQol 5‐Dimension, 5‐Level (EQ‐5D‐5L), were completed at baseline, Week 13, and every 12 weeks until disease progression. PRO endpoints were time to first confirmed clinically meaningful deterioration (TTFCD) in HRQoL or pain. Subgroups included prognostic risk, pain/HRQoL, prior docetaxel, and local therapy (radical prostatectomy [RP] and/or radiotherapy [RT]). Results: There were several between‐treatment differences in TTFCD for pain and functioning/HRQoL PROs. Enzalutamide plus ADT delayed TTFCD for worst pain in the prior RT group (not reached vs. 14.06 months; hazard ratio [HR]: 0.56 [95% confidence interval: 0.34−0.94]) and pain interference in low‐baseline‐HRQoL group (19.32 vs. 11.20 months; HR: 0.64 [0.44−0.94]) versus placebo plus ADT. In prior/no prior RP, prior RT, prior local therapy, no prior docetaxel, mild baseline pain, and low‐risk subgroups, TTFCD was delayed for the EQ‐5D‐5L visual analog scale. Conclusion: Enzalutamide plus ADT provides clinical benefits in defined patient subgroups versus ADT alone, while maintaining lack of pain and high HRQoL, with delayed deterioration in several HRQoL measures.